Head-to-head · WeighScore
CoraDoc vs RxPros
By GLP-1 ScorecardUpdated
Score comparison
CoraDoc has the higher recorded score — 76.8/100 to 69.3/100.
CoraDoc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. CoraDoc advertises one upfront payment for a selected GLP-1 program. Its sales page and written refund policy give different answers about what you may get back.
Before you choose
Before comparing the headline prices, the CoraDoc review and the RxPros review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, CoraDoc vs SnagRx and CoreAge Rx vs RxPros compare each of them with another graded program, and the list of alternatives to CoraDoc ranks the programs closest to CoraDoc on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Collective review covers one graded close to these two, at 71.6/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoraDoc | RxPros |
|---|---|---|
| WeighScore | 76.8/100 | 69.3/100 |
| Grade | C | C |
| Site position | #49 | #144 |
| Semaglutide | $924 upfront (12-month promotion, compounded) | $100/mo (annual plan, compounded) |
| Tirzepatide | $1,524 upfront (12-month promotion, compounded) | $145/mo (annual plan, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- The 12-month promotion publishes the one-time payment for each medication
- The campaign lists clinician visits, medication, dose increases, shipping and supplies as included
- The weight-loss campaign advertises no automatic renewal for the annual offer
What to consider
- The lowest advertised monthly equivalents require paying for 12 months at once
- The refund policy describes a possible $100 clinical fee after medical ineligibility, despite the sales-page full-refund promise
- The pages checked did not name the dispensing pharmacy for an individual order
Strengths
- $99.99/month compounded semaglutide — among the cheapest in the US compounded telehealth market
- $144.97/month compounded tirzepatide — at the lower end of the compounded tirzepatide range
- LegitScript Certified
- Named legal entity (RxPros LLC) with a physical Wyoming address
- Overnight cold-packed shipping disclosed — important for GLP-1 cold-chain integrity
What to consider
- Per-state availability not listed — verify your state ships before committing
- Specific 503A pharmacy partners not named
- Lab work not included as standard
- LegitScript certification number not displayed (seal only)
- Lowest headline prices ($99.99 sema / $144.97 tirz) require annual prepay; intro-first-month/quarterly tier is $134.99 sema / $224.99 tirz
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.